Standards in advertising. Has Didronel PMO been proved to protect against osteoporosis?
作者信息
Millson D, Clark W
出版信息
BMJ. 1999 Jan 30;318(7179):330.
Abstract
摘要
相似文献
1
Standards in advertising. Has Didronel PMO been proved to protect against osteoporosis?广告标准。Didronel PMO是否已被证明可预防骨质疏松症？
BMJ. 1999 Jan 30;318(7179):330.
2
Didronel PMO.
Nurs Times. 2005;101(27):31.
3
Didronel PMO.羟乙膦酸钠片
Br J Hosp Med. 1993;49(4):275-7.
4
Intermittent etidronate and corticosteroid-induced osteoporosis.
N Engl J Med. 1997 Dec 25;337(26):1921. doi: 10.1056/NEJM199712253372613.
5
Etidronate and glucocorticoid induced osteoporosis.依替膦酸二钠与糖皮质激素所致骨质疏松症
J Rheumatol. 2005 Jan;32(1):199-200.
6
[Asthma--prevention of glucocorticoid-induced osteoporosis with etidronate and calcium].
Pneumologie. 2005 Feb;59(2):94. doi: 10.1055/s-2005-863759.
7
Monthly risedronate (Actonel) for postmenopausal osteoporosis.每月使用利塞膦酸盐（阿屈膦酸盐）治疗绝经后骨质疏松症。
Med Lett Drugs Ther. 2008 Sep 8;50(1294):69-70.
8
[Corticosteroid-induced osteoporosis-- prevention and treatment].
Harefuah. 1999 Mar 15;136(6):489-92.
9
Sophie's bones: a case study in osteoporosis.索菲的骨骼：骨质疏松症的一个案例研究
Adv Nurse Pract. 2004 Sep;12(9):39-40, 42.
10
Alendronate (Fosamax) and risedronate (Actonel) revisited.
Obstet Gynecol. 2005 Aug;106(2):402-4. doi: 10.1097/01.AOG.0000173817.16040.97.
本文引用的文献
1
Risk factors for osteoporotic fracture.骨质疏松性骨折的危险因素。
Endocrinol Metab Clin North Am. 1998 Jun;27(2):289-301. doi: 10.1016/s0889-8529(05)70006-2.
2
Intermittent etidronate and corticosteroid-induced osteoporosis.
N Engl J Med. 1997 Dec 25;337(26):1921. doi: 10.1056/NEJM199712253372613.
3
Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis.间歇性依替膦酸疗法预防皮质类固醇诱导的骨质疏松症。
N Engl J Med. 1997 Aug 7;337(6):382-7. doi: 10.1056/NEJM199708073370603.
Zotero 插件